Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection

AIDS. 2003 May 2;17(7):1086-9. doi: 10.1097/00002030-200305020-00021.

Abstract

We studied 14 patients acutely infected with wild-type HIV, who underwent supervised treatment interruptions after initial antiretroviral treatment including lamivudine. Lamivudine resistance mutations emerged for the first time during supervised treatment interruptions in one patient. Resistance should be monitored in supervised treatment interruptions trials, because mutations may first be detected only after therapy is interrupted.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active / methods
  • Drug Resistance, Viral / genetics*
  • Genes, pol / genetics*
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / therapeutic use*
  • HIV-1 / genetics*
  • Humans
  • Lamivudine / therapeutic use
  • Mutation / genetics*
  • RNA, Viral / blood

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors
  • RNA, Viral
  • Lamivudine